DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Alpelisib
Alpelisib
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
Alpelisib Plus Fulvestrant in PIK3CA-Altered
Systemic Treatment Landscape and Algorithm for Hormone-Receptor Positive, HER2 Negative Advanced Breast Cancer
Combined Pi3kα-Mtor Targeting of Glioma Stem Cells
Alpelisib (Piqray®) EOCCO POLICY
Systemic Treatment of Metastatic Breast Cancer: SABCS 2018
Rucaparib Approved for Ovarian Cancer Anti-CD22 CAR Therapy
Ribociclib + Fulvestrant + PI3K Inhibitor
NCCN Guidelines for Patients Metastatic Breast Cancer
November 2019
January 2021 Forward-Looking Statements and Disclaimer
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Metastatic Breast Cancer (MBC) in 2019
A Phase II Randomized, Double-Blind Placebo Controlled, Study Of
Breast Cancer 2
Drugs with Special Ordering Procedures (SAP Chart)
Separately Chargeable Drugs List
Top View
Patient-Derived Organoids and High Grade Serous Ovarian Cancer
Efficacy and Safety of PARP Inhibitor Combination Therapy In
Novartis Q4 and FY 2019 Results | January 29, 2020 | Novartis Investor Presentation Participants
Alpelisib Combined with Low Dose Mifepristone for Treating Advanced
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Download Supplementary
(Alpelisib Or Buparlisib) for HR+ Advanced Breast Cancer
Oncology Center of Excellence 2020 Annual Report
Download Our Report Guide
Piqray; INN-Alpelisib
Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com
Adult Antiemetic Management of Chemotherapy-Induced Nausea
State and Specialty Pharmacy Drug Reimbursement Rates
Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
Novel Targeted Drugs Approved by the NMPA and FDA in 2019
Appendix a - Product Name Index
Oncology Agents Policy #: Rx.01.67
BYL719, Alpelisib SOLAR-1
Proton Pump Inhibitors and Oncologic Treatment Efficacy
Preclinical Evaluation of Ribociclib and Its Synergistic Effect in Combination
Oncology Proposal
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
State and Specialty Pharmacy Drug Reimbursement Rates
TAG Mail – 17 Dec 2020
Proficiency and Poly (ADP-Ribose) Polymerase Inhibitor (Parpi) Resistance
BKM120 Sensitizes Glioblastoma to the PARP Inhibitor Rucaparib By
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER
Q4-2020-Investor-Presentation.Pdf
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
Combating Pancreatic Cancer with PI3K Pathway Inhibitors in the Era Of
PI3K-Targeting Strategy Using Alpelisib to Enhance the Antitumor Effect Of
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Patient-Specific Network for Personalized Breast Cancer
2019-03 INN Report
Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
Smart Approaches for the Effective Treatment of Breast Cancer
Chemotherapeutic and Biologic Drugs
Potent Antineoplastic Effects of Combined Pi3kα–MNK Inhibition In
Do Not Tube List
Investor Presentation July 21, 2020 Disclaimer
Oncology Oral Medications Enrollment Form
Summary of Safety and Effectiveness Data (Ssed)
PARP) Inhibitor Olaparib And
November 2020
List Item Applications for New Human
Foundationone® Liquid Cdx Technical Information
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor
2021 Pacificsource Health Plans Prior Authorization Criteria Last Modified